



NEWS RELEASE

Pfizer Ltd's Profit from operations before other income, finance cost and tax for the Quarter increased by 40%

Pfizer Ltd announced the results for the first quarter ended June 30, 2014.

The revenue for the quarter was ₹240 crore as compared to ₹237 crore in the same period last year.

The financial results are not strictly comparable with the same period last year as last year period includes the transition support for sales of certain animal health products. Excluding these transactions the revenues for the quarter would reflect a growth of 10%.

Profit from operations before other income, finance cost and tax reflects a growth of 40%.

The EBDITA margins have improved to 26% as compared to 19% in the same period last year.

Profit before tax for the quarter is lower by ₹3 crore, from ₹73 crore in the same period last year to ₹70 crore during the quarter, primarily due to lower interest income.



Contacts -

Investors:

Prajeet Nair

Pfizer Ltd

Ph: +91-22-66932352

Email: prajeet.nair@pfizer.com

Media:

Sherry Varghese

Pfizer Ltd

Ph: +91-9619914505

Email: sherry.varghese@pfizer.com

About Pfizer Ltd:

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 60 years in India, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizerindia.com

Disclaimer

The information contained in this press release is only current as of its date. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care of in the press release and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this press release or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries where such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this press release, independent consultation / advice may be obtained and necessary due diligence, investigation etc. may be done at your end.